Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC. (NVAX)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
2.12(c) 1.98(c) 1.61(c) 1.65(c) 1.73 Last
86 922 670 40 803 264 31 553 571 10 845 428 11 061 706 Volume
+59.40% -6.60% -18.69% +2.48% +4.85% Change
More quotes
Financials ($)
Sales 2017 28,8 M
EBIT 2017 -168 M
Net income 2017 -180 M
Debt 2017 175 M
Yield 2017 -
Sales 2018 27,5 M
EBIT 2018 -182 M
Net income 2018 -195 M
Debt 2018 251 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 24,1x
EV / Sales2018 27,9x
Capitalization 517 M
More Financials
Company
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants.Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus,... 
More about the company
Surperformance© ratings of Novavax, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVAVAX, INC.
01/12 Respiratory Syncytial Virus Infections– Unmet Needs in Adult Targeted D..
01/11 NOVAVAX, INC. : Today’s Research Reports on Stocks to Watch: Novavax, Inc. and T..
01/10 NOVAVAX, INC. (NASDAQ : NVAX) Files An 8-K Termination of a Material Definitive ..
01/09 NOVAVAX INC : Termination of a Material Definitive Agreement (form 8-K)
01/08 NOVAVAX INC : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
2017 NOVAVAX INC : Other Events, Financial Statements and Exhibits (form 8-K)
2017 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Novavax, Inc...
2017 NOVAVAX : Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal ..
2017 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novavax, Inc. (..
2017 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc..
More news
Sector news : Biotechnology & Medical Research - NEC
08:48a CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/15B. Riley Lowers Novavax Q3 2018 Earnings Estimates to ($0.16) EPS (Previously.. 
01/14Analysts Expect Novavax, Inc. $NVAX Will Announce Quarterly Sales of $8.32 Mi..
1
01/13B.Riley FBR Sticks to Its Buy Rating for Novavax $NVAX
2
01/12Friday’s Midday Stock Update: Novavax (NVAX), Arrowhead Research (ARWR), Terr.. 
01/12JPM18: Novavax investors cheer RSV vaccine update, then pull back: Biopharma .. 
More tweets
Qtime:135
News from SeekingAlpha
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
01/12 Midday Gainers / Losers (1/12/2018)
01/12 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (1/12/2018)
01/12 YOUR DAILY PHARMA SCOOP : AbbVie Highlights Pipeline, Novavax Surges, Lipocine F..
01/11 NOVAVAX : Is This Time Different?
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700021040 | 4-Traders
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 3,15 $
Spread / Average Target 91%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, CEO, Chief Financial Officer & Director
James F. Young Chairman
Timothy Jon Hahn Senior VP-Global Manufacturing Operations
Louis F. Fries Chief Medical Officer & Senior Vice President
Michael A. McManus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.29.84%517
CELLTRION, INC.--.--%41 248
IQVIA HOLDINGS INC2.19%20 807
LONZA GROUP0.42%20 432
INCYTE CORPORATION-0.68%19 852
ALNYLAM PHARMACEUTICALS, INC.1.59%12 692